NCT07459595

Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Fatima Tariq · Academic / Other
• Sex: Female
• Age: 16 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound. The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.

Conditions

• Polycystic Ovarian Syndrome (PCOS)

Interventions

Type	Name	Description
DRUG	Myoinositol	In group A, females will be prescribed oral myoinositol 1g twice daily for 3 months.
DRUG	Metformin	In group B, females will be prescribed oral sustained-release metformin 850 mg twice daily for 3 months.

Timeline

• Start date: 2026-05-01
• Primary completion: 2026-07-31
• Completion: 2026-07-31
• First posted: 2026-03-10
• Last updated: 2026-03-10

Locations

1 site across 1 country: Pakistan